Published on 24 Nov 2020

Materiality of Superbugs

Investors are starting to forecast a post-pandemic world. As part of these efforts, it is crucial that they understand and manage the risks of antimicrobial resistance (AMR). If left unchecked, AMR is set to substantially undermine the global economy’s financial recovery and future outlook. Here, Mara Lilley and Sana Johnson run through the main risks and opportunities presented by superbugs for pharma companies and resources available for navigating through them.

Explore further

Get in touch

Back to top |